Department of Pediatric Neurology, Diyarbakır Children's Hospital, Diyarbakır, Turkey.
Department of Pediatric Cardiology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Neuromuscul Disord. 2019 Apr;29(4):290-295. doi: 10.1016/j.nmd.2019.02.004. Epub 2019 Feb 19.
Cardiac autonomic dysfunction has been examined in myasthenia gravis but not in congenital myasthenic syndromes (CMS). We aimed to evaluate cardiac autonomic functions in genetically defined CMS. Patients diagnosed with and under treatment for CMS were reviewed for 24-hour cardiac rhythm monitoring. Heart rate variability (HRV) measures were defined as: SDNN, mean of the standard deviations for all R-R intervals; SDNNi, standard deviation of all R-R intervals in successive five-minute epochs; RMSSD, square root of the mean of squared differences between successive R-R intervals. Ten patients with mutations in the epsilon subunit of the acetylcholine receptor (AChRε) and five patients with mutations in the collagen-like tail of asymmetric acetylcholinesterase (ColQ) were included. Median age at evaluation was 17 (2.5-46) years. In the AChRε group, RMSSD values; and in the ColQ group, SDNN, SDNNi and RMSSD values were significantly lower than those of healthy subjects. This first extensive report examining HRV in CMS showed alterations in patients with ColQ mutations and, to a lesser extent, in the group with AChRε mutations. This might indicate an increased risk of cardiac arrhythmias. We suggest cardiological follow-up in CMS, and consideration of any potential cardiovascular effects of therapeutic agents used in management.
心脏自主神经功能障碍已在重症肌无力中进行了检查,但在先天性肌无力综合征 (CMS) 中尚未进行检查。我们旨在评估基因定义的 CMS 中的心脏自主功能。对诊断为 CMS 并正在接受治疗的患者进行了 24 小时心脏节律监测的回顾性分析。心率变异性 (HRV) 测量值定义为:SDNN,所有 R-R 间隔标准差的平均值;SDNNi,连续五个五分钟时段的所有 R-R 间隔的标准差;RMSSD,连续 R-R 间隔之间均方根差的平方根。纳入了 10 名乙酰胆碱受体 (AChRε) ε 亚基突变和 5 名不对称乙酰胆碱酯酶胶原样尾部 (ColQ) 突变的患者。评估时的中位年龄为 17 岁(2.5-46 岁)。在 AChRε 组中,RMSSD 值;在 ColQ 组中,SDNN、SDNNi 和 RMSSD 值均明显低于健康受试者。这是第一项广泛研究 CMS 中 HRV 的报告,显示了 ColQ 突变患者和 AChRε 突变患者中存在变化,而 AChRε 突变患者的变化程度较小。这可能表明心律失常的风险增加。我们建议对 CMS 进行心脏随访,并考虑用于管理的任何潜在心血管效应的治疗药物。